Cephalon, Inc. (CEPH) & EPCT ?
"The company has a strong pipeline, and growing oncology line (up 179% y-o-y) , for which margins are very high, nearly $10 share cash, and will continue to make acquisitions. The $700M just raised will not be dillutive long, in my opinion, as the company seeks to grow. "
If I hit "report abuse" everytime I read an insulting or negative post, it would be about 100 a day. Multiply that by one million message board readers, and well, you do the math.
I am so sick of people who whine like babies everytime they hear something they don't like. Grow up and get a real life that includes more important things to worry and get upset about.
If there is someone whom you are annoyed with, that's what the "ignore" feature is for. Use it, crybaby!
There is one more important reason:
Neuropathic Pain and NP-1.
“Following the recent negative FDA advice on Cephalon's Fentora, Datamonitor has forecast that the drug will not launch for neuropathic pain. This is a blow to the development of a niche breakthrough neuropathic pain market.”
epct is as you can see a perfect match !
The statement below summarizes the need and difficulty to develop medicine in the field of oncology (AML).
"We made a significant financial investment in this pioneering effort to develop lestaurtinib for this molecularly targeted patient population with a poor prognosis and few treatment options," Frank Baldino (photo), Cephalon and CEO said in a statement."
I total agree about AML.
Investors just bot $750 million of new issue CEPH common and converts. The price was at a discount, yes but If the outlook was poor - investors wouldn't be putting nearly a billion $ of fresh capital into the company.
The market is voting that CEPH can make attractive, accretive acquisitions with the cash.
And why not invest in epct?